Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alcohol Dependence Treatment Vivitrol “Approvable”

This article was originally published in The Pink Sheet Daily

Executive Summary

Alkermes/Cephalon expect to launch the renamed once-monthly naltrexone injection in the second quarter.

You may also be interested in...



Vivitrol Approved Labeling Leaves Room For Broad Marketing Plan

Naltrexone is the first FDA-approved extended-release monthly alcohol dependence drug, Alkermes and Cephalon say.

Vivitrol Approved Labeling Leaves Room For Broad Marketing Plan

Naltrexone is the first FDA-approved extended-release monthly alcohol dependence drug, Alkermes and Cephalon say.

Alkermes Submits Vivitrol Complete Response

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel